Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017

Home/Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017

Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017

Drug Pipeline, Drug Discovery, Pharma & Healthcare

Publication ID:

GBI0817003

Publication Date:

August 01, 2017

Pages:

254

Publisher:

GBI Research

Region:

Global

$3,995.00

Need Custom Market Research Solution?

Want to commission a custom market research to suit your needs? We are here to help. Let us know.

Printer version

Send by email

PDF version

Tabs

Description

Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017

Summary

This report provides an overview of the pipeline landscape for neuropsychiatric disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), Depression, Schizophrenia, and Tourette syndrome, and features dormant and discontinued projects.

Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness, with symptoms including disorganized work habits, procrastination and inability to sustain attention on tasks or activities.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches.

Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior.

Finally, Tourette syndrome is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking.

The size of these pipelines ranges from 11 products in Tourette syndrome to 191 in depression. Across all four of these indications, however, transporters and receptors of neurotransmitters such as dopamine and serotonin are the most common targets, closely reflecting the current treatment landscape of these diseases.

Scope

- Which companies are the most active within the pipeline for genetic neuropsychiatric disorder therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of genetic neuropsychiatric disorders?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

Table of Contents
GBI Research Report Guidance 2
Executive Summary 3
Table of Contents 4
List of Tables 6
List of Figures 12
Introduction 13
Neuropsychiatric Disorder Cluster Report Coverage 13
Attention Deficit Hyperactivity Disorder (ADHD) - Overview 13
Depression - Overview 13
Schizophrenia - Overview 13
Tourette Syndrome - Overview 13
Therapeutics Development 14
Attention Deficit Hyperactivity Disorder (ADHD) 14
Depression 22
Schizophrenia 36
Tourette Syndrome 47
Therapeutics Assessment 50
Attention Deficit Hyperactivity Disorder (ADHD) 50
Depression 57
Schizophrenia 68
Tourette Syndrome 78
Companies Involved in Therapeutics Development 84
Attention Deficit Hyperactivity Disorder (ADHD) 84
Depression 101
Schizophrenia 148
Tourette Syndrome 185
Dormant Projects 189
Attention Deficit Hyperactivity Disorder (ADHD) 189
Depression 192
Schizophrenia 201
Tourette Syndrome 206
Discontinued Products 207
Attention Deficit Hyperactivity Disorder (ADHD) 207
Depression 208
Schizophrenia 211
Tourette Syndrome 212
Product Development Milestones 213
Attention Deficit Hyperactivity Disorder (ADHD) 213
Depression 224
Schizophrenia 233
Tourette Syndrome 243
Appendix 253
Methodology 253
Coverage 253
Secondary Research 253
Primary Research 253
Expert Panel Validation 253
Contact Us 253
Disclaimer 254

List of Tables
List of Tables
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD) 14
Number of Products under Development by Companies, Attention Deficit Hyperactivity Disorder (ADHD) 16
Number of Products under Development by Universities/Institutes, Attention Deficit Hyperactivity Disorder (ADHD) 17
Products under Development by Companies, Attention Deficit Hyperactivity Disorder (ADHD) 18
Products under Development by Universities/Institutes, Attention Deficit Hyperactivity Disorder (ADHD) 21
Number of Products under Development for Depression 22
Number of Products under Development by Companies, Depression 24
Number of Products under Development by Universities/Institutes, Depression 27
Products under Development by Companies, Depression 28
Products under Development by Universities/Institutes, Depression 34
Number of Products under Development for Schizophrenia 36
Number of Products under Development by Companies, Schizophrenia 38
Number of Products under Development by Universities/Institutes, Schizophrenia 40
Products under Development by Companies, Schizophrenia 41
Products under Development by Universities/Institutes, Schizophrenia 46
Number of Products under Development for Tourette Syndrome 47
Number of Products under Development by Companies, Tourette Syndrome 48
Number of Products under Development by Universities/Institutes, Tourette Syndrome 49
Products under Development by Companies, Tourette Syndrome 49
Products under Development by Universities/Institutes, Tourette Syndrome 49
Number of Products by Stage and Target, Attention Deficit Hyperactivity Disorder (ADHD) 51
Number of Products by Stage and Mechanism of Action, Attention Deficit Hyperactivity Disorder (ADHD) 53
Number of Products by Stage and Route of Administration, Attention Deficit Hyperactivity Disorder (ADHD) 55
Number of Products by Stage and Molecule Type, Attention Deficit Hyperactivity Disorder (ADHD) 56
Number of Products by Stage and Target, Depression 58
Number of Products by Stage and Mechanism of Action, Depression 62
Number of Products by Stage and Route of Administration, Depression 66
Number of Products by Stage and Molecule Type, Depression 68
Number of Products by Stage and Target, Schizophrenia 70
Number of Products by Stage and Mechanism of Action, Schizophrenia 73
Number of Products by Stage and Route of Administration, Schizophrenia 76
Number of Products by Stage and Molecule Type, Schizophrenia 78
Number of Products by Stage and Target, Tourette Syndrome 79
Number of Products by Stage and Mechanism of Action, Tourette Syndrome 81
Number of Products by Stage and Route of Administration, Tourette Syndrome 83
Number of Products by Stage and Molecule Type, Tourette Syndrome 83
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Aevi Genomic Medicine Inc 84
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Alcobra Ltd 84
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Amarantus Bioscience Holdings Inc 85
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by APeT Holding BV 85
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Arbor Pharmaceuticals LLC 86
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BCWorld Pharm Co Ltd 86
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BioHealthonomics Inc 87
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BioLite Inc 87
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Cingulate Therapeutics LLC 88
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Collegium Pharmaceutical Inc 88
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Curemark LLC 89
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by DURECT Corp 89
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Eli Lilly and Company 90
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Ensysce Biosciences Inc 90
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by H. Lundbeck A/S 91
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Heptares Therapeutics Ltd 91
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Highland Therapeutics Inc 92
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Integrative Research Laboratories Sweden AB 92
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by INVENT Pharmaceuticals Inc 93
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by KemPharm Inc 93
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Luc Therapeutics Inc 94
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Merck & Co Inc 94
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Neos Therapeutics Inc 95
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NeuroDerm Ltd 95
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Neurovance Inc 96
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NLS Pharma Group 96
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Noven Pharmaceuticals Inc 97
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by P2D Bioscience 97
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Reviva Pharmaceuticals Inc 98
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Shire Plc 98
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by SK Biopharmaceuticals Co Ltd 99
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Sunovion Pharmaceuticals Inc 99
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Supernus Pharmaceuticals Inc 100
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Taisho Pharmaceutical Co Ltd 100
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by TRImaran Pharma Inc 101
Depression - Pipeline by 4D Pharma PLC 101
Depression - Pipeline by AB Science SA 102
Depression - Pipeline by Acadia Pharmaceuticals Inc 102
Depression - Pipeline by Adamed Sp z oo 103
Depression - Pipeline by Addex Therapeutics Ltd 103
Depression - Pipeline by Aequus Pharmaceuticals Inc 104
Depression - Pipeline by Alkermes Plc 104
Depression - Pipeline by Allergan Plc 105
Depression - Pipeline by Alvogen Korea Co Ltd 105
Depression - Pipeline by Amorsa Therapeutics Inc 106
Depression - Pipeline by Anavex Life Sciences Corp 106
Depression - Pipeline by Angelini Group 107
Depression - Pipeline by Angita BV 107
Depression - Pipeline by Araim Pharmaceuticals Inc 107
Depression - Pipeline by AstraZeneca Plc 108
Depression - Pipeline by Avanir Pharmaceuticals Inc 108
Depression - Pipeline by Axsome Therapeutics Inc 109
Depression - Pipeline by Azevan Pharmaceuticals Inc 109
Depression - Pipeline by BioCrea GmbH 110
Depression - Pipeline by BioLite Inc 110
Depression - Pipeline by Bionomics Ltd 111
Depression - Pipeline by Boehringer Ingelheim GmbH 111
Depression - Pipeline by Bristol-Myers Squibb Company 112
Depression - Pipeline by Calico LLC 112
Depression - Pipeline by Celgene Corp 113
Depression - Pipeline by Celon Pharma SA 113
Depression - Pipeline by Cerecor Inc 114
Depression - Pipeline by Clera Inc 114
Depression - Pipeline by Delpor Inc 115
Depression - Pipeline by Domain Therapeutics SA 115
Depression - Pipeline by Eisai Co Ltd 116
Depression - Pipeline by Eli Lilly and Company 116
Depression - Pipeline by Evotec AG 117
Depression - Pipeline by F. Hoffmann-La Roche Ltd 117
Depression - Pipeline by Fabre-Kramer Pharmaceuticals Inc 118
Depression - Pipeline by FPRT Bio Inc 118
Depression - Pipeline by GlaxoSmithKline Plc 119
Depression - Pipeline by GliaCure Inc 119
Depression - Pipeline by H. Lundbeck A/S 120
Depression - Pipeline by Heptares Therapeutics Ltd 120
Depression - Pipeline by Hua Medicine (Shanghai) Ltd 121
Depression - Pipeline by Hyundai Pharmaceutical Co Ltd 121
Depression - Pipeline by Impel NeuroPharma Inc 122
Depression - Pipeline by INSYS Therapeutics Inc 122
Depression - Pipeline by Intas Pharmaceuticals Ltd 123
Depression - Pipeline by Intra-Cellular Therapies Inc 123
Depression - Pipeline by INVENT Pharmaceuticals Inc 124
Depression - Pipeline by Johnson & Johnson 124
Depression - Pipeline by KemPharm Inc 125
Depression - Pipeline by Lead Discovery Center GmbH 125
Depression - Pipeline by Les Laboratoires Servier SAS 126
Depression - Pipeline by Lixte Biotechnology Holdings Inc 126
Depression - Pipeline by Luye Pharma Group Ltd 127
Depression - Pipeline by Mapi Pharma Ltd 127
Depression - Pipeline by Mapreg SAS 128
Depression - Pipeline by Medlab Clinical Ltd 128
Depression - Pipeline by Meta-IQ ApS 129
Depression - Pipeline by Methylation Sciences Inc 129
Depression - Pipeline by miCure Therapeutics Ltd 130
Depression - Pipeline by Mitsubishi Tanabe Pharma Corp 130
Depression - Pipeline by Navya Biologicals Pvt Ltd 131
Depression - Pipeline by Neuralstem Inc 131
Depression - Pipeline by Neurocrine Biosciences Inc 132
Depression - Pipeline by NeuroNascent Inc 132
Depression - Pipeline by NeurOp Inc 133
Depression - Pipeline by Newron Pharmaceuticals SpA 133
Depression - Pipeline by Nippon Chemiphar Co Ltd 134
Depression - Pipeline by nLife Therapeutics SL 134
Depression - Pipeline by Omeros Corp 135
Depression - Pipeline by Orexigen Therapeutics Inc 135
Depression - Pipeline by Otsuka Holdings Co Ltd 136
Depression - Pipeline by Pfizer Inc 137
Depression - Pipeline by Pherin Pharmaceuticals Inc 137
Depression - Pipeline by Polleo Pharma Ltd 138
Depression - Pipeline by Protagenic Therapeutics Inc 138
Depression - Pipeline by Relmada Therapeutics Inc 139
Depression - Pipeline by Reviva Pharmaceuticals Inc 139
Depression - Pipeline by Richter Gedeon Nyrt 140
Depression - Pipeline by Sage Therapeutics Inc 140
Depression - Pipeline by Saniona AB 141
Depression - Pipeline by SK Biopharmaceuticals Co Ltd 141
Depression - Pipeline by Sound Pharmaceuticals Inc 142
Depression - Pipeline by Sumitomo Dainippon Pharma Co Ltd 142
Depression - Pipeline by Supernus Pharmaceuticals Inc 143
Depression - Pipeline by Suven Life Sciences Ltd 143
Depression - Pipeline by Taisho Pharmaceutical Holdings Co Ltd 144
Depression - Pipeline by Takeda Pharmaceutical Company Ltd 144
Depression - Pipeline by Tetra Discovery Partners LLC 145
Depression - Pipeline by Trevena Inc 145
Depression - Pipeline by TRImaran Pharma Inc 146
Depression - Pipeline by VistaGen Therapeutics Inc 146
Depression - Pipeline by Zhejiang Huahai Pharmaceutical Co Ltd 147
Depression - Pipeline by Zogenix Inc 147
Depression - Pipeline by Zysis Ltd 148
Schizophrenia - Pipeline by Acadia Pharmaceuticals Inc 148
Schizophrenia - Pipeline by Adamed Sp z oo 149
Schizophrenia - Pipeline by Aequus Pharmaceuticals Inc 149
Schizophrenia - Pipeline by AgeneBio Inc 150
Schizophrenia - Pipeline by Alkermes Plc 150
Schizophrenia - Pipeline by Angita BV 151
Schizophrenia - Pipeline by Astellas Pharma Inc 151
Schizophrenia - Pipeline by Athersys Inc 152
Schizophrenia - Pipeline by Avanir Pharmaceuticals Inc 152
Schizophrenia - Pipeline by Avineuro Pharmaceuticals Inc 153
Schizophrenia - Pipeline by BCWorld Pharm Co Ltd 153
Schizophrenia - Pipeline by BioCrea GmbH 154
Schizophrenia - Pipeline by BioHealthonomics Inc 154
Schizophrenia - Pipeline by Boehringer Ingelheim GmbH 154
Schizophrenia - Pipeline by Braeburn Pharmaceuticals Inc 155
Schizophrenia - Pipeline by Bristol-Myers Squibb Company 155
Schizophrenia - Pipeline by Critical Pharmaceuticals Ltd 156
Schizophrenia - Pipeline by Curemark LLC 156
Schizophrenia - Pipeline by Daewoong Pharmaceutical Co Ltd 157
Schizophrenia - Pipeline by Delpor Inc 157
Schizophrenia - Pipeline by Denovo Biopharma LLC 158
Schizophrenia - Pipeline by Evotec AG 158
Schizophrenia - Pipeline by F. Hoffmann-La Roche Ltd 159
Schizophrenia - Pipeline by Fabre-Kramer Pharmaceuticals Inc 159
Schizophrenia - Pipeline by Galenea Corp 160
Schizophrenia - Pipeline by GeNeuro SA 160
Schizophrenia - Pipeline by GlaxoSmithKline Plc 161
Schizophrenia - Pipeline by Glenmark Pharmaceuticals Ltd 161
Schizophrenia - Pipeline by GP Pharm SA 162
Schizophrenia - Pipeline by GW Pharmaceuticals Plc 162
Schizophrenia - Pipeline by H. Lundbeck A/S 163
Schizophrenia - Pipeline by Heptares Therapeutics Ltd 163
Schizophrenia - Pipeline by Hisamitsu Pharmaceutical Co Inc 164
Schizophrenia - Pipeline by Indivior Plc 164
Schizophrenia - Pipeline by Insys Therapeutics Inc 165
Schizophrenia - Pipeline by IntelGenx Corp 165
Schizophrenia - Pipeline by Intra-Cellular Therapies Inc 166
Schizophrenia - Pipeline by Johnson & Johnson 166
Schizophrenia - Pipeline by JT Pharmaceuticals Inc 167
Schizophrenia - Pipeline by Karuna Pharmaceuticals Inc 167
Schizophrenia - Pipeline by KemPharm Inc 168
Schizophrenia - Pipeline by Kowa Company Ltd 168
Schizophrenia - Pipeline by Laboratorios Farmaceuticos Rovi SA 169
Schizophrenia - Pipeline by Lead Discovery Center GmbH 169
Schizophrenia - Pipeline by Lohocla Research Corp 170
Schizophrenia - Pipeline by Luye Pharma Group Ltd 170
Schizophrenia - Pipeline by Mapi Pharma Ltd 171
Schizophrenia - Pipeline by Merck & Co Inc 171
Schizophrenia - Pipeline by Mitsubishi Tanabe Pharma Corp 172
Schizophrenia - Pipeline by Neurocrine Biosciences Inc 172
Schizophrenia - Pipeline by NeurOp Inc 173
Schizophrenia - Pipeline by Newron Pharmaceuticals SpA 173
Schizophrenia - Pipeline by Omeros Corp 174
Schizophrenia - Pipeline by Otsuka Holdings Co Ltd 175
Schizophrenia - Pipeline by Peptron Inc 175
Schizophrenia - Pipeline by Pfizer Inc 176
Schizophrenia - Pipeline by Promentis Pharmaceuticals Inc 176
Schizophrenia - Pipeline by Ra Pharmaceuticals Inc 177
Schizophrenia - Pipeline by Reviva Pharmaceuticals Inc 177
Schizophrenia - Pipeline by Richter Gedeon Nyrt 178
Schizophrenia - Pipeline by Sage Therapeutics Inc 178
Schizophrenia - Pipeline by SK Biopharmaceuticals Co Ltd 179
Schizophrenia - Pipeline by Sumitomo Dainippon Pharma Co Ltd 179
Schizophrenia - Pipeline by Sunovion Pharmaceuticals Inc 180
Schizophrenia - Pipeline by Suven Life Sciences Ltd 180
Schizophrenia - Pipeline by Taisho Pharmaceutical Holdings Co Ltd 181
Schizophrenia - Pipeline by Tetra Discovery Partners LLC 181
Schizophrenia - Pipeline by Teva Pharmaceutical Industries Ltd 182
Schizophrenia - Pipeline by Vanda Pharmaceuticals Inc 182
Schizophrenia - Pipeline by Vitality Biopharma Inc 183
Schizophrenia - Pipeline by VLP Therapeutics LLC 183
Schizophrenia - Pipeline by Zogenix Inc 184
Schizophrenia - Pipeline by Zysis Ltd 184
Tourette Syndrome - Pipeline by Abide Therapeutics Inc 185
Tourette Syndrome - Pipeline by Catalyst Pharmaceuticals Inc 185
Tourette Syndrome - Pipeline by Neurocrine Biosciences Inc 186
Tourette Syndrome - Pipeline by Psyadon Pharmaceuticals Inc 186
Tourette Syndrome - Pipeline by Reviva Pharmaceuticals Inc 187
Tourette Syndrome - Pipeline by Synchroneuron Inc 187
Tourette Syndrome - Pipeline by Teva Pharmaceutical Industries Ltd 188
Tourette Syndrome - Pipeline by Therapix Biosciences Ltd 188
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects 189
Depression - Dormant Projects 192
Schizophrenia - Dormant Projects 201
Tourette Syndrome - Dormant Projects 206
Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products 207
Depression - Discontinued Products 208
Schizophrenia - Discontinued Products 211
Tourette Syndrome - Discontinued Products 212

List of Figures
List of Figures
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD) 14
Number of Products under Development by Companies, Attention Deficit Hyperactivity Disorder (ADHD) 15
Number of Products under Development by Universities/Institutes, Attention Deficit Hyperactivity Disorder (ADHD) 17
Number of Products under Development for Depression 22
Number of Products under Development by Companies, Depression 23
Number of Products under Development by Universities/Institutes, Depression 27
Number of Products under Development for Schizophrenia 36
Number of Products under Development by Companies, Schizophrenia 37
Number of Products under Development by Universities/Institutes, Schizophrenia 40
Number of Products under Development for Tourette Syndrome 47
Number of Products under Development by Companies, Tourette Syndrome 48
Number of Products by Top 10 Targets, Attention Deficit Hyperactivity Disorder (ADHD) 50
Number of Products by Stage and Top 10 Targets, Attention Deficit Hyperactivity Disorder (ADHD) 50
Number of Products by Top 10 Mechanism of Actions, Attention Deficit Hyperactivity Disorder (ADHD) 52
Number of Products by Stage and Top 10 Mechanism of Actions, Attention Deficit Hyperactivity Disorder (ADHD) 52
Number of Products by Routes of Administration, Attention Deficit Hyperactivity Disorder (ADHD) 54
Number of Products by Stage and Routes of Administration, Attention Deficit Hyperactivity Disorder (ADHD) 54
Number of Products by Molecule Types, Attention Deficit Hyperactivity Disorder (ADHD) 55
Number of Products by Stage and Molecule Types, Attention Deficit Hyperactivity Disorder (ADHD) 56
Number of Products by Top 10 Targets, Depression 57
Number of Products by Stage and Top 10 Targets, Depression 57
Number of Products by Top 10 Mechanism of Actions, Depression 61
Number of Products by Stage and Top 10 Mechanism of Actions, Depression 61
Number of Products by Top 10 Routes of Administration, Depression 65
Number of Products by Stage and Top 10 Routes of Administration, Depression 65
Number of Products by Molecule Types, Depression 67
Number of Products by Stage and Molecule Types, Depression 67
Number of Products by Top 10 Targets, Schizophrenia 68
Number of Products by Stage and Top 10 Targets, Schizophrenia 69
Number of Products by Top 10 Mechanism of Actions, Schizophrenia 72
Number of Products by Stage and Top 10 Mechanism of Actions, Schizophrenia 72
Number of Products by Routes of Administration, Schizophrenia 75
Number of Products by Stage and Routes of Administration, Schizophrenia 75
Number of Products by Molecule Types, Schizophrenia 77
Number of Products by Stage and Molecule Types, Schizophrenia 77
Number of Products by Top 10 Targets, Tourette Syndrome 78
Number of Products by Stage and Top 10 Targets, Tourette Syndrome 79
Number of Products by Top 10 Mechanism of Actions, Tourette Syndrome 80
Number of Products by Stage and Top 10 Mechanism of Actions, Tourette Syndrome 80
Number of Products by Top 10 Routes of Administration, Tourette Syndrome 82
Number of Products by Stage and Routes of Administration, Tourette Syndrome 82
Number of Products by Stage and Molecule Types, Tourette Syndrome 83

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Report Enquiry

Do you need more information about this report before making a purchase decision or wish to customize this report to suite your requirements?

If yes, then please use the form given below and we will get in touch with you immediately.

Kindly use your official email address and contact number to ensure speedy response.

Name *

Email *

Company

Contact Number *

Report Title *

Your Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Drag or click the correct shape to the grey "drop area".